Skip to main content

Table 2 Best objective response assessed per RECIST (version 1.1) by investigator review (n = 15)

From: Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot study

Best objective response

No

%

95% CI

ORR

3

20.0

7.1–45.2

DCR

13

86.7

62.1–96.3

PR

3

20.0

7.1–45.2

SD

10

66.6

41.7–84.8

PD

2

13.3

3.7–37.9